News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
39 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57662)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37441)
2025 (33090)
2026 (24639)
Month
January (2434)
February (2868)
March (3029)
April (3116)
May (3356)
June (2727)
July (2287)
August (2492)
September (2330)
Day
1 (180)
2 (176)
3 (167)
4 (36)
6 (28)
7 (20)
8 (209)
9 (212)
10 (153)
11 (45)
13 (31)
14 (133)
15 (141)
16 (97)
17 (129)
18 (39)
20 (21)
21 (93)
22 (125)
23 (162)
24 (113)
25 (20)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
Day
1
2
3
4
6
7
8
9
10
11
13
14
15
16
17
18
20
21
22
23
24
25
Press Releases
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 18, 2026
September 18, 2026
·
2 min read
Press Releases
CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy
September 18, 2026
·
14 min read
Press Releases
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
September 18, 2026
·
13 min read
Press Releases
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
September 18, 2026
·
5 min read
Press Releases
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
September 18, 2026
·
1 min read
Cancer
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
Bristol Myers Squibb acquired the degrader-antibody conjugate from Orum Therapeutics in 2023 for $100 million upfront and the possibility of up to $80 million more in milestones.
September 18, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Velocity Clinical Research appoints Justin Starzyk as Chief Executive Officer
September 18, 2026
·
4 min read
Press Releases
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
September 18, 2026
·
8 min read
Press Releases
Sandoz Canada receives Health Canada regulatory approval for (Pr)Sandoz® Semaglutide, a generic version of (Pr)Ozempic®
September 18, 2026
·
4 min read
Press Releases
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
September 18, 2026
·
12 min read
Previous
3 of 4
Next
